GlassScriptPhysician profile
Yu Eun Hwang
NPI 1285046490
$9,037.23
in general payments reported to CMS, 2019-2025
25 companies · $1,546 in 2025
The $1,546 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,109 · 2022: $1,476 · 2023: $1,968 · 2024: $1,940 · 2025: $1,546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,087 · Travel and Lodging: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,086.66 |
| Travel and Lodging | $366.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,956.58 | 2021-2025 | |
| Axonics, INC. | $726.72 | 2023 | Axonics |
| Takeda Pharmaceuticals U.S.A., INC. | $532.25 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $516.78 | 2021-2024 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $414.23 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $374.67 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $367.83 | 2021-2023 | |
| Janssen Biotech, INC. | $323.30 | 2021-2025 | Tremfya, Stelara |
| E.R. Squibb & Sons, L.L.C. | $321.63 | 2021-2024 | |
| Pfizer INC. | $238.58 | 2021-2025 | |
| Gilead Sciences, INC. | $235.26 | 2021-2024 | |
| Aimmune Therapeutics, INC. | $153.95 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $148.03 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $140.76 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $117.52 | 2024-2025 | Iqirvo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $117.30 | 2021-2024 | Dificid |
| Lilly USA, LLC | $110.71 | 2024 | Omvoh |
| Braintree Laboratories, INC. | $70.81 | 2021-2025 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $37.74 | 2023-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $31.52 | 2021 | |
| Vivus LLC | $28.12 | 2025 | Pancreaze |
| Novo Nordisk INC | $27.40 | 2025 | Wegovy |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.83 | 2022 | |
| Orphalan INC | $15.55 | 2024 | Cuvrior |
| Intra-Sana Laboratories | $10.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yu Eun Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.